Prescribe by brand name

• 5mg & 10mg tablets
• 5mg, 10mg, 20mg, 30mg and 40mg m/r capsules (Medikinet® XL)
• 10mg, 20mg & 30mg m/r capsules (Equasym® XL)
• 18mg, 27mg, 36mg & 54mg m/r tablets (first choice: Atenza® XL; second choice: Xaggitin® XL)
  
  • Existing patients who are prescribed Concerta® XL should be reviewed and switched to Atenza® XL as appropriate
  • Atenza XL and Xaggitin XL are bioequivalent to Concerta XL
• 2mg/ml oral solution sugar free (Consilient Health Ltd). Only for those patients unable to take solid dosage forms across the whole dosage range. This preparation contains the following excipients with known effect: Propylene glycol 90mg/ml, Sorbitol 175mg/ml, Sodium benzoate 1mg/ml NPPG Position statement ‘Choosing an Oral Liquid Medicine for Children’ advises on maximum content of propylene glycol and benzoates dependent on age.
• Approved for ADHD and the treatment of narcolepsy in adult and paediatrics.
• Approved for improving working memory and processing speed following neurocognitive damage secondary to brain injury from; a brain tumour and its associated treatment (e.g. hydrocephalus and radiotherapy) or neurotoxic chemotherapy.

• MHRA Drug Safety Update (Sep 2022): Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations

• 10mg, 18mg, 25mg, 40mg, 60mg, 80mg & 100mg capsules
• 4mg/1ml oral solution - approved for patients with more complex needs e.g. younger patients and those with swallowing difficulties.

• 5mg, 10mg and 20mg tablets
  • ADHD
  • Narcolepsy
  • Doses up to 60mg daily 

• 20mg, 30mg, 40mg, 50mg, 60mg & 70mg capsules
  • For third line use and specialist initiation. Should only transferred to GPs after at least three month stable symptom control
  • Approved for the treatment of ADHD in adults

• Approved for:
  
  • treatment of patients with narcolepsy
  • treatment of idiopathic hypersomnia
  
  
  

• 75mg and 150mg tablet
  • Approved for treating excesive daytime sleepiness caused by narcolepsy in line with NICE

• Approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
• To be used in line with NTAG

• 1mg, 2mg, 3mg & 4mg prolonged release tablets
  • Approved for use in children and adolescents when 1st line stimulants and atomoxetine are contraindicated or ineffective.
  • Can also be prescribed in primary care by GPs in adults who started treatment in childhood and wish to continue, for whom stimulants are not suitable, not tolerated or have been shown to be ineffective under specialist supervision